Valuation: Scilex Holding Company

Market Cap 46.87M 40.75M 37.93M 34.82M 65.76M 4.47B 66.78M 447M 175M 2.23B 176M 172M 7.47B P/E 2024
-0.7x
P/E 2025 -0.33x
Enterprise Value 168M 146M 136M 125M 236M 16.08B 240M 1.61B 630M 8B 633M 619M 26.84B EV / Sales 2024
2.08x
EV / Sales 2025 6.49x
Free-Float
19.23%
Yield 2024 *
-
Yield 2025 -
1 day+0.98%
1 week-2.56%
1 month-14.66%
3 months-37.00%
6 months-27.08%
Current year-45.37%
1 week 6.44
Extreme 6.44
7.15
1 month 6.44
Extreme 6.44
10.43
Current year 4.2
Extreme 4.2
14.05
1 year 4.2
Extreme 4.2
34.27
3 years 3.6
Extreme 3.6
222.25
5 years 3.6
Extreme 3.6
591.5
10 years 3.6
Extreme 3.6
591.5
Manager TitleAgeSince
Chief Executive Officer 61 17/08/2025
Director of Finance/CFO 53 22/09/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 62 10/11/2022
Director/Board Member 53 22/09/2025
Director/Board Member 62 22/09/2023
Date Insider Type Main position Quantity % Market Cap.
12/26/25 A SellCompany 20,657,300 272.3281%
10/8/25 A Free

Director

20,000 0.2991%
10/8/25 A Free

Director

20,000 0.2991%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%-2.56%-50.30%-96.83% 46.87M
+0.32%-0.66%+64.21%+23.18% 322B
+0.21%+2.87%+33.60%-10.00% 71.6B
-0.91%+0.74%+39.85%+92.63% 9.79B
-2.98%-6.71%-3.20%-8.73% 8.39B
+1.80%-1.99%-15.78%-13.19% 4.3B
-0.68%-1.87%-34.78%+6.01% 3.81B
+3.08%-1.41%-12.94%+15.81% 3.58B
-2.15%-3.40%+25.70%+41.55% 2.59B
+0.85%+9.88%-0.25%-3.21% 2.25B
Average +0.07%-0.56%+4.61%+4.72% 42.79B
Weighted average by Cap. +0.23%-0.09%+54.29%+17.97%

Financials

2024 2025
Net sales 56.59M 49.19M 45.79M 42.04M 79.39M 5.4B 80.62M 540M 212M 2.69B 213M 208M 9.02B 30.25M 26.3M 24.48M 22.47M 42.44M 2.89B 43.1M 289M 113M 1.44B 114M 111M 4.82B
Net income -72.81M -63.29M -58.91M -54.09M -102M -6.95B -104M -694M -273M -3.46B -273M -267M -11.6B -359M -312M -290M -266M -503M -34.24B -511M -3.42B -1.34B -17.05B -1.35B -1.32B -57.17B
Net Debt 41.49M 36.06M 33.57M 30.82M 58.2M 3.96B 59.1M 396M 155M 1.97B 156M 152M 6.61B 122M 106M 98.36M 90.31M 171M 11.6B 173M 1.16B 455M 5.78B 457M 447M 19.37B
Logo Scilex Holding Company
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Employees
34
Date Price Change Volume
31/07/26 $6.665 +0.98% 100,041
30/07/26 $6.600 +0.61% 112,080
29/07/26 $6.560 -3.81% 100,630
28/07/26 $6.820 -2.99% 112,133
27/07/26 $7.030 +2.78% 120,142

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCLX Stock